Key result
Local recurrence within 6 months of definitive radiotherapy for scalp angiosarcoma was significantly associated with overall survival (p=0.003) and cancer-specific survival (p=0.0001).
Why the study?
It was unclear whether initial local treatment effect affects overall survival when definitive radiotherapy is administered for localised scalp angiosarcoma.
Does local recurrence within 6 months of definitive radiotherapy affect overall survival and cancer-specific survival in patients with localized scalp angiosarcoma?
Cohort (n=31)
No
Does local recurrence within 6 months of definitive radiotherapy affect overall survival and cancer-specific survival in patients with localized scalp angiosarcoma?
Local recurrence within 6 months of definitive radiotherapy for scalp angiosarcoma is significantly associated with worse overall and cancer-specific survival, and reduces quality of life due to severe symptoms.
Early recurrence may flag high-risk scalp angiosarcoma patients for intensified surveillance; leaves open whether intervention improves survival.
INTRODUCTION: Scalp angiosarcoma is a rare and aggressive cancer. Definitive radiotherapy is a treatment option for localised scalp angiosarcoma patients. Although definitive surgical resection reportedly prolongs overall survival (OS), whether initial local treatment effect affects OS when definitive radiotherapy is administered is unclear. Therefore, this study analysed whether local recurrence within 6 months of irradiation correlates with OS and cancer-specific survival (CSS). Furthermore, how local control affects patients' quality of life was investigated. MATERIALS AND METHODS: Thirty-one localised scalp angiosarcoma patients who had received definitive radiotherapy at our institution between October 2010 and July 2021 were analysed retrospectively. The most commonly used dose fractionation was 70 Gy in 35 fractions (83.9%). Local recurrence within 6 months of radiotherapy and other clinical factors were examined in univariate and subsequent multivariate analyses for correlation with OS and CSS. RESULTS: The median follow-up period was 16 months (range, 6-45 months). Local recurrence was detected in 16 patients (51.6%), 12 of whom had recurrence within 6 months. In multivariate analyses, the presence of local recurrence within 6 months of radiotherapy was significantly associated with OS and CSS (p = 0.003, 0.0001, respectively). Ten of the 16 patients with local recurrence had severe symptoms such as bleeding, pain, difficulty opening the eye and malodour. CONCLUSIONS: The initial local treatment effect was significantly associated with OS and CSS after definitive radiotherapy. Furthermore, local recurrence after radiotherapy resulted in a variety of symptoms, including bleeding and pain, which reduced the patient's quality of life.
No takes yet. Share an insight, caveat, or question.
Kashihara et al. (2022) conducted a cohort in Localised scalp angiosarcoma (n=31). Local recurrence within 6 months of radiotherapy vs. No local recurrence within 6 months was evaluated on Overall survival (OS) and cancer-specific survival (CSS) (p=0.003 for OS, 0.0001 for CSS). Local recurrence within 6 months of definitive radiotherapy for scalp angiosarcoma was significantly associated with overall survival (p=0.003) and cancer-specific survival (p=0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: